Franz-Werner Haas (Photo by THOMAS KIENZLE / AFP) (Photo by THOMAS KIENZLE/AFP via Getty Images)
CureVac establishes RNA printer-specific company as light at the end of tunnel nears
When CureVac CEO Franz-Werner Haas attended the inaugural mRNA health conference in 2013, there were just 80 people in attendance, largely from Moderna, BioNTech and his own company. Nine years later, there were nearly 1,000 people there.
Five years from now, Haas says, there will be groups of people from companies whose names he’s never heard of, thanks to the recent success and rapid development of mRNA technology. But they all face a key challenge.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
